Back to Agenda
The State of Artificial Intelligence in Regulatory Review and Decision-Making: Perspectives from FDA, EMA, PMDA, and CDE
Session Chair(s)
Jingyu (Julia) Luan, PHD
Executive Regulatory Science Director, BioPharmaceuticals R&D
AstraZeneca, United States
Senior leaders from FDA, EMA, PMDA, and CDE share insights on AI’s evolving role in regulatory review & decision-making. Attendees will explore current practices, key challenges, and future opportunities for AI in shaping global regulatory frameworks.
Learning Objective : Discover how AI is transforming regulatory review and decision-making at FDA, EMA, PMDA and CDE; Analyze key challenges and opportunities facing AI adoption in regulatory review and decision-making; Identify emerging trends and future directions for AI in shaping global regulatory practices.
Have an account?